文献速递关节外科

以价值为基础的商业保险项目对髋膝关节置换术是否仍可行:单机构分析

Are Commercial Value-Based Care Programs Still Viable for Hip and Knee Arthroplasty: An Analysis of a Single Institution.
PubMed 文献 · J Arthroplasty · 2025-05-06

单中心单支付方价值医疗项目回顾4,285例初次全髋/全膝关节置换患者(2020年1月至2023年4月),商业保险2,916例、联邦医疗保险优势计划1,369例。商业保险患者总费用和设施费用下降、盈余增加,优势计划患者费用仅小幅下降、盈余减少;两组日间手术中心使用率均上升。作者认为将合适患者按需求匹配至低成本设施仍可维持商业价值医疗合作,但在优势计划中未取得同样控费效果。

要点

  • 商业保险患者总费用从33,455美元降至27,433美元,设施费用从25,068美元降至18,385美元,盈余从6,216美元升至13,090美元。
  • 联邦医疗保险优势计划患者总费用从17,809美元降至17,235美元,设施费用从13,491美元降至13,151美元,盈余从7,928美元降至4,073美元。
  • 日间手术中心使用率商业保险从1%升至20%,优势计划从0.3%升至12%。

核心结论

  • 将合适患者按需求匹配至低成本设施,可使诊所与商业保险公司维持成功的价值医疗合作。
  • 本研究的控费措施在联邦医疗保险优势计划中未取得同样成功。
  • 作者认为需进一步研究优势计划持续削减是否会威胁可及性。

研究设计与样本

  • 回顾性分析单中心单支付方价值医疗项目,纳入2020年1月至2023年4月连续4,285例初次全髋关节置换和全膝关节置换患者。
  • 按保险类型分为商业保险2,916例(68%)和联邦医疗保险优势计划1,369例(32%),比较4年间设施使用、总费用和盈余趋势。

主要发现

  • 商业保险患者平均总费用从2020年33,455美元降至2023年27,433美元(P < 0.001),平均设施费用从25,068美元降至18,385美元(P < 0.001),盈余从6,216美元升至13,090美元(P < 0.001)。
  • 联邦医疗保险优势计划患者平均总费用从17,809美元降至17,235美元(P < 0.001),平均设施费用从13,491美元降至13,151美元(P < 0.001),盈余从7,928美元降至4,073美元(P < 0.001)。
  • 日间手术中心使用率从2020年至2023年两组均上升:商业保险从1%升至20%,优势计划从0.3%升至12%(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unlike Medicare bundled payment programs for total hip arthroplasty and total knee arthroplasty, which have little variance in facility reimbursements, few publications have studied value-based care (VBC) partnerships with commercial insurers. Specifically, VBC partnerships incentivize practices to maximize revenue surpluses by providing high-value care at decreased costs. Surgical facility choice can reduce costs with more procedures shifting to lower-cost specialty hospitals and ambulatory surgery centers. This study aimed to determine whether demand matching appropriate patients to lower-cost facilities reduced costs in our commercial VBC program. METHODS: We reviewed a consecutive series of 4,285 primary total hip arthroplasty and total knee arthroplasty patients between January 2020 and April 2023 as part of a single-payer VBC program, including both commercial and Medicare Advantage (MA) plans. Demographics, facility, and 90-day episode-of-care claims data were collected from our clinical and payor cost databases. Surgical facility utilization, total costs, and revenue surpluses were stratified by insurance type (commercial versus MA), and trends were compared over the 4-year study period. There were 1,369 patients (32%) who had MA and 2,916 (68%) who had commercial insurance. RESULTS: Among commercially insured patients, the mean total ($33,455 versus $27,433, P < 0.001) and facility costs ($25,068 versus $18,385, P < 0.001) both declined from 2020 to 2023, whereas the revenue surpluses ($6,216 versus $13,090, P < 0.001) increased. Among MA patients, mean total ($17,809 versus $17,235, P < 0.001) and facility costs ($13,491 versus $13,151, P < 0.001) had only minimal decreases, whereas revenue surpluses declined ($7,928 versus $4,073, P < 0.001). Utilization of ambulatory surgery centers increased among both groups from 2020 to 2023 (1 versus 20% for commercial, 0.3 versus 12% for MA, P < 0.001). CONCLUSIONS: Practices can still have successful VBC partnerships with private insurers by demand matching appropriate patients to lower-cost facilities. Our cost-reduction efforts did not have the same success with MA plans. Further studies should evaluate whether continued cuts to MA programs will threaten access.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Abe EA, Parikh N, Nemirov DA, et al. Are Commercial Value-Based Care Programs Still Viable for Hip and Knee Arthroplasty: An Analysis of a Single Institution. J Arthroplasty. 2025. PMID: 40339937. doi:10.1016/j.arth.2025.04.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。